Encompass Health Corp Dossier - Source-backed chat

Encompass Health Corp

EHCNYSE

SectorHealth Care

IndustryMedical Care Facilities

Beta (adjusted)0.83

Intrinsic Value $115.69median of 6 methods · middle span $94-$150based on filings through 30 Jun 2026

Market Price $119.06Price as of 1 Oct 2026

Near fair valueIntrinsic value is 3% below the market price

−50% · IV below pricenear fair value ±15%IV above price · +50%

Data confidence Sign in to view data confidence

Market Cap $11.7B

Enterprise Value $14.2B

Shares Outstanding 100.3M diluted

Moat Rating Wide

Next Earnings Date2 Nov 2026

Last ex-dividend1 Oct 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Encompass Health entered the second half of 2026 with strong operating momentum: second-quarter revenue increased 9.6%, adjusted EBITDA increased 9.2%, same-store discharges increased 2.8%, and management raised full-year revenue, adjusted EBITDA and adjusted EPS guidance. Capacity expansion and a larger share-repurchase authorization support the outlook, but reimbursement exposure, labor intensity and execution risk around hospital openings remain material.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets12 analysts · as of 18 Aug 2026

Low · most bearish analyst$140.00

Mean target$148.17

High · most bullish analyst$155.00

Street targets sit above today's price; our intrinsic value sits below it. Different horizons, different questions.

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 2 Sep 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$140.0020%

The bear case assumes revenue or adjusted EBITDA falls below updated guidance because of weaker volumes, reimbursement pressure, elevated labor costs or slower-than-planned maturation of new capacity.

Base CaseCentral scenario

$148.1755%

Matches the consensus mean

The base case assumes results remain within updated 2026 guidance, same-store discharges stay positive, and planned hospital and bed additions proceed without material cost or timing disruption.

Bull CaseUpside scenario

$155.0025%

The bull case requires performance above the upper end of updated 2026 guidance, continued positive same-store discharge growth, successful completion and ramp-up of the five additional hospitals expected during the second half, and accretive execution of the expanded repurchase authorization.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Second-quarter 2026 net operating revenue increased 9.6% year over year to USD 1,597.4 million, while adjusted EBITDA increased 9.2% to USD 348.0 million.
Same-store discharges increased 2.8% in the second quarter, and the company expected five additional hospital openings plus more than 100 beds at existing facilities before year-end.
Management raised all three principal 2026 guidance ranges, and the board increased the aggregate common-stock repurchase authorization to USD 1 billion.

Key Investment Risks

Labor remains a major operating exposure: salaries and benefits were USD 820.3 million in the second quarter, and the company identifies staffing shortages and competitive compensation as risks.
Revenue and cash flow remain exposed to Medicare and Medicaid reimbursement changes, payment reviews, claim denials and broader healthcare regulation.
The expansion program is capital- and execution-intensive; purchases of property, equipment and intangible assets reached USD 382.7 million in the first half of 2026.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.